Cancer drugs, Sport and the offshore pharmacy

passdrugtest — Thu, 31 Dec 2009 14:06:05 +0000

Many Pharmacy drugs are used today for onlabel use like to treat cancer that are of real medical use but many of the same drugs are also used by athletes nothing only to get an edge but it has become the norm. Buying from an Mexican Pharmacy is normal no matter if you live in Australia, America, NZ, Japan or any other place in the world any offshore pharmacy on the internet can supply you with medication depending on if they require a prescription or not some Pharmacies will fill your order without the need for a prescription.

Alot of people are now using an Offshore Pharmacy to reduce their costs and to get better access to cheaper Generic drugs that work just as well.

Why would anyone spend years of hard work when you can build the same speed or power up in 1 years that it takes a natural sportman 5 years. No wonder more and more people are turning to chemicals for help. Many products are can be purchased without much problems like from online and offshore pharmacies. An offshore pharmacy or at times called a mexican pharmacy or a canadian pharmacy offer many people the chance to save money of have access to drugs they just cant get but many people from all around the world are now using them to buy medications to help them in sport.

The claim that Nolvadex reduces gains should not be taken too seriously. The belief that it reduces gains seems to stem from the fact that the scientific literature reports a slight reduction in IGF-1 (individuals using anabolic steroids were not studied though) from use of Nolvadex. Thus, Dan Duchaine reported that it reduces IGF-1 and therefore reduces gains. However, if this effect exists at all, it must be very minor, due to the excellent gains that many have made, and from the fact that no one has noticed any such thing from Clomid, which has the same activity profile. Clomid and Nolvadex are both pharmacy medication and you should have a RX for these and can be found for sale at many offshore pharmacy sites.how to find them just goto google and type in Offshore pharmacy.

Tamoxifen citrate is the chemical name of active ingredient in Nolvadex.

Tamoxifen citrate has a molecular weight of 563.62, the pKa’ is 8.85, the equilibrium solubility in water at 37°C is 0.5 mg/mL and in 0.02 N HCl at

37°C, it is 0.2 mg/mL. CLINICAL PHARMACOLOGY

NOLVADEX is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be

Tamoxifen inhibits the induction of rat mammary

carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model,

45 ng/mL) occurred approximately 5 hours after dosing. The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination halflife

of about 5 to 7 days. The average peak plasma concentration of N-desmethyl tamoxifen is 15 ng/mL (range 10 to 20 ng/mL). Chronic administration

for tamoxifen and 336 ng/mL (range 148-654 ng/mL) for N-desmethyl tamoxifen. The average steady-state plasma concentrations of tamoxifen and

N-desmethyl tamoxifen after administration of 20 mg tamoxifen once daily for 3 months are 122 ng/mL (range 71-183 ng/mL) and 353 ng/mL (range

After initiation of therapy, steady state concentrations for tamoxifen are achieved in about 4 weeks and steady-state

concentrations for N-desmethyl tamoxifen are achieved in about 8 weeks, suggesting a half-life of approximately 14 days for this metabolite. Clinical Studies – Adjuvant Breast Cancer

Overview – The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) conducted worldwide overviews of systemic adjuvant therapy for early

breast cancer in 1985, 1990, and again in 1995. In 1998, 10-year outcome data were reported for 36,689 women in 55 randomized trials of adjuvant

Twenty-five percent of patients received 1 year or less of trial treatment, 52% received 2 years,

and 23% received about 5 years. no adjuvant therapy and 42% were entered into trials comparing NOLVADEX in combination with chemotherapy vs. the same chemotherapy alone.

Among these patients, 54% had node positive disease and 46% had node negative disease.

Among women with ER positive or unknown breast cancer and positive nodes who received about 5 years of treatment, overall survival at 10 years

was 61.4% for NOLVADEX Offshore pharmacy vs. The recurrence-free rate at 10 years was 59.7% for NOLVADEX vs. control (logrank 2p < 0.00001). Among women with ER positive or unknown breast cancer and negative nodes who received about 5 years of treatment,

overall survival at 10 years was 78.9% for NOLVADEX vs. 73.3% for control (logrank 2p < 0.00001). The recurrence-free rate at 10 years was 79.2%

64.3% for control (logrank 2p < 0.00001).

In women with ER positive or unknown breast cancer receiving 1 year

or less, 2 years or about 5 years of NOLVADEX, the proportional reductions in mortality were 12%, 17%, and 26%, respectively (trend significant at

2p < 0.003). Benefit is less clear for women with ER poor breast cancer in whom the proportional reduction in recurrence was 10% (2p = 0.007) for all durations

taken together, or 9% (2p = 0.02) if contralateral breast cancers are excluded. about 5 years of NOLVADEX on recurrence and mortality were similar regardless of age and concurrent chemotherapy. doses greater than 20 mg per day were more effective.

Node Positive – Individual Studies – Two studies (Hubay and NSABP B-09) demonstrated an improved disease-free survival following radical or

modified radical mastectomy in postmenopausal women or women 50 years of age or older with surgically curable breast cancer with positive axillary

nodes when NOLVADEX was added to adjuvant cytotoxic chemotherapy. In the Hubay study, NOLVADEX was added to “low-dose” CMF (cyclophosphamide,

In the NSABP B-09 study, NOLVADEX was added to melphalan [L-phenylalanine mustard (P)] and fluorouracil

(F).

Effects on the liver: Liver cancer: In the Swedish trial using adjuvant NOLVADEX 40 mg/day for 2-5 years, 3 cases of liver cancer have been reported

in the NOLVADEX-treated group vs. 1 case in the observation group (see PRECAUTIONS – Carcinogenesis). In other clinical trials evaluating NOLVADEX,

no cases of liver cancer have been reported to date.

Effects on the liver: Non-malignant effects: NOLVADEX has been associated with changes in liver enzyme levels, and on rare occasions, a spectrum

of more severe liver abnormalities including fatty liver, cholestasis, hepatitis and hepatic necrosis. A few of these serious cases included fatalities. In

most reported cases the relationship to NOLVADEX is uncertain. NOLVADEX). Serum lipids were not systematically collected.

Other cancers: A number of second primary tumors, occurring at sites other than the endometrium, have been reported following the treatment of

Effects on the Eye: Ocular disturbances, including corneal changes, decrement in color vision perception, retinal vein thrombosis, and retinopathy

have been reported in patients receiving NOLVADEX. An increased incidence of cataracts and the need for cataract surgery have been reported in patients

receiving NOLVADEX.

In the NSABP P-1 trial, an increased risk of borderline significance of developing cataracts among those women without cataracts at baseline

(540-NOLVADEX; 483-placebo; RR=1.13, 95% CI: 1.00-1.28) was observed. risk of having cataract surgery (101-NOLVADEX; 63-placebo; RR=1.62, 95% CI: 1.17-2.25) (See Table 3 in CLINICAL PHARMACOLOGY). Among all

women on the trial (with or without cataracts at baseline), NOLVADEX was associated with an increased risk of having cataract surgery (201-NOLVADEX;

129-placebo; RR=1.51, 95% CI: 1.21-1.89). No other conclusions regarding non-cataract

ophthalmic events can be made.

Women should be advised not to become

pregnant while taking NOLVADEX or within 2 months of discontinuing NOLVADEX and should use barrier or nonhormonal contraceptive measures if

sexually active. Tamoxifen does not cause infertility, even in the presence of menstrual irregularity. Effects on reproductive functions are expected

In reproductive studies in rats at dose levels equal to or below the human dose, nonteratogenic developmental

skeletal changes were seen and were found reversible. In addition, in fertility studies in rats and in teratology studies in rabbits using doses

Several pregnant marmosets were dosed with

10 mg/kg/day (about 2-fold the daily maximum recommended human dose on a mg/m2 basis) during organogenesis or in the last half of pregnancy.

No deformations were seen and, although the dose was high enough to terminate pregnancy in some animals, those that did maintain pregnancy

showed no evidence of teratogenic malformations. Offshore Pharmacy

Why use an Offshore Pharmacy and why so many people use them and will always use them?

Easy they are alot cheaper then your local pharmacy and an offshore pharmacy is cheap

No matter who you are and what you need always speak to your doctor and read information on what you are taking this can help you to be safe after all its your body and you need to keep yourself healthy if you need some more information check out this Offshore Pharmacy they are the best around and they have alot of good information on the products they stock and are ranked as a great offshore pharmacy by the 10000’s of people that use a offshore pharmacy every day.

passdrugtesting.net » Offshore Pharmacy

Cancer drugs, Sport and the offshore pharmacy